NeuBase Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
350 Technology Drive, Pittsburgh, PA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Ohr Pharmaceutical Inc (to 7/12/2019), BBM HOLDINGS, INC. (to 8/17/2009), PRIME RESOURCE INC (to 3/23/2007)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 411 % -50.3%
Debt-to-equity 65.9 % +130%
Return On Equity -104 % -6.35%
Return On Assets -62.4 % +17.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.73M shares
Common Stock, Shares, Outstanding 3.73M shares -88.7%
Entity Public Float 57.9M USD
Common Stock, Value, Issued 373 USD -88.7%
Weighted Average Number of Shares Outstanding, Basic 2.76M shares +70.8%
Weighted Average Number of Shares Outstanding, Diluted 2.76M shares +70.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.26M USD -80.1%
General and Administrative Expense 9.12M USD -23.2%
Operating Income (Loss) -15.3M USD +54.2%
Nonoperating Income (Expense) 1.54M USD +984%
Net Income (Loss) Attributable to Parent -13.7M USD +59.4%
Earnings Per Share, Basic -2.95 USD/shares +72%
Earnings Per Share, Diluted -2.95 USD/shares +72%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.6M USD -45.7%
Accounts Receivable, after Allowance for Credit Loss, Current 150K USD
Assets, Current 13.4M USD -45.8%
Property, Plant and Equipment, Net 79.7K USD -96.3%
Operating Lease, Right-of-Use Asset 5.06M USD -9.81%
Other Assets, Noncurrent 0 USD -100%
Assets 18.6M USD -43%
Accounts Payable, Current 259K USD -86%
Accrued Liabilities, Current 462K USD -72.2%
Liabilities, Current 4.65M USD +11.6%
Operating Lease, Liability, Noncurrent 4.83M USD -9.39%
Liabilities 9.48M USD -0.18%
Retained Earnings (Accumulated Deficit) -116M USD -13.4%
Stockholders' Equity Attributable to Parent 9.14M USD -60.6%
Liabilities and Equity 18.6M USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.45M USD +57.9%
Net Cash Provided by (Used in) Financing Activities -88.4K USD -226%
Net Cash Provided by (Used in) Investing Activities -4.95K USD +96.7%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 3.73M shares -88.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.54M USD +57.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.6M USD -45.7%
Deferred Tax Assets, Valuation Allowance 29.2M USD +48.4%
Deferred Tax Assets, Gross 31M USD +54.9%
Operating Lease, Liability 5.89M USD -4.67%
Depreciation 700K USD -12.5%
Payments to Acquire Property, Plant, and Equipment 13.4K USD -90.9%
Lessee, Operating Lease, Liability, to be Paid 8.01M USD -8.3%
Property, Plant and Equipment, Gross 291K USD -91.6%
Operating Lease, Liability, Current 501K USD -9.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 874K USD +0.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 965K USD +17.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.12M USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three 881K USD +0.81%
Deferred Tax Assets, Operating Loss Carryforwards 22.5M USD +69.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 889K USD +0.82%
Additional Paid in Capital 126M USD -0.26%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense -240K USD -108%
Interest Expense 5.07K USD -78.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%